Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fiber fix? inulin may supercharge GLP-1 Weight-Loss drugs for heart health

NCT ID NCT07611552

Disease control Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking inulin, a type of dietary fiber, can improve cholesterol and other heart-related risk factors in 600 overweight or obese adults who are already using GLP-1 medications (like semaglutide) for weight loss. Participants will take either 10 grams of inulin or a placebo daily for 4 months. The goal is to see if adding this simple supplement can make these popular weight-loss drugs even better for long-term heart health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
inulin (a type of dietary fiber/prebiotic)
What this could lead to
If it works, adding inulin to GLP-1 medications could improve cholesterol and triglyceride levels, making weight-loss treatments better for heart health.
What could go wrong
This is an early-stage supplement study, not a drug trial. The effect may be small or not noticeable, and gastrointestinal side effects like diarrhea or constipation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Be overweight or obese (meeting any of the following criteria): 1. Obesity: BMI \>=28 kg/m²; 2. Overweight (BMI \>= 24 kg/m²) with at least one body weight-related comorbidity: obstructive sleep apnea syndrome, prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia, polycystic ovary syndrome, or non-alcoholic fatty liver disease. * Must have received GLP-1 RA drugs (Semaglutide, Liraglutide, Benaglutide, Tirzepatide, or Mazdutide) for weight-loss intervention for at least 3 months, and plan to continue using them for the next six months. * Age 18-64 years. * Consent to participate and sign the informed consent form. Exclusion criteria: * Currently using non-GLP-1 RA medications for weight-loss, or have undergone or plan to undergo weight-loss procedures within the next 4 months; * Long-term user of prebiotics or probiotics (excluding fermented dairy products such as yogurt); * Be allergic or intolerance to inulin-type substances; * Have participated in in other clinical trials within the past 3 months or are currently participating in other clinical trials; * Plan to be pregnant within the next year, are currently pregnant, or are breastfeeding; * Deemed unsuitable for participation by the investigator's judgment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Sinopharm Dongfeng General Hospital

    Shiyan, Hubei, China

  • The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture

    Enshi, Hubei, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Xiangyang No.1 People's Hospital

    Xiangyang, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.